Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma - An experience from a Medical Center in Southern Taiwan

C. I. Hsieh, W. C. Su, C. H. Chien, Y. L. Cuo, T. Y. Chen, R. H. Kao, C. J. Tsao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A retrospective analysis was performed of 117 non-Hodgkin's lymphoma (NHL) patients (72 male and 45 female, mean age 55 years) treated at NCKUH between July 1988 and December 1993. Of the 115 patients who could be classified by Ann Arbor staging system, 26 patients (22.2%) were in stage 1; 23 (19.7%) in stage 2; 29 (24.8%) in stage 3; and 37 (31.6%) in stage 4. According to the International Working Formulation, three patients (2.6%) were low grade NHL, 90 (76.9%) were intermediate, and 8 (6.8%) were high grade NHL. Histologically, diffuse large cell NHL accounted for 52.1% of cases, followed by 16.2% of cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting B-cell origin, 17 (18%) cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting, B-cell-origin, 17 (18%) cases exhibiting T-cell origin and 2 (2%) cases were of null cell type. All patients underwent two groups of induction chemotherapy, either CHOP (Cyclophosphamide, Epirubicin, Oncovin, and Prednisolone) or 'modified' COPBLAM (Cyclophosphamide, Epirubicin, Oncovin, Vinblastine, Bleomycin, Procarbazine, and Prednisolone). Seventy-two cases treated through COPBLAM and 45 cases treated through CHOP were evaluated. The response rate (RR) to COPBLAM treatment was 72.2% and was 68.9% for the CHOP group (P = 0.51). The 5-year overall survival rate (OAS) was 44.1% for COPBLAM, versus 40% for CHOP (P = 0.15). The disease-free survival (DFS) was 72.6% at 63 months for COPBLAM and 58% at 51 months for CHOP (P = 0.16). Neither B cell nor T-cell lineages of NHL showed any statistical difference in RR (P = 0.53), DFS (P = 0.58) or OAS (P = 0.97) to the different treatments. Using multiple logistic analysis, two independent factors, high LDH and advanced stage, were found to adversely affect the rate of complete remission. The application of the International Prognostic Index to our patients needs modification, which suggests the necessity of more evaluation before it can accurately be applied to all international series of NHL.

Original languageEnglish
Pages (from-to)69-82
Number of pages14
JournalKaohsiung Journal of Medical Sciences
Volume12
Issue number2
Publication statusPublished - Mar 25 1996
Externally publishedYes

Fingerprint

Combination Drug Therapy
Taiwan
Non-Hodgkin's Lymphoma
Epirubicin
Vincristine
Prednisolone
Cyclophosphamide
B-Lymphocytes
Disease-Free Survival
Survival Rate
Procarbazine
T-Lymphocytes
Null Lymphocytes
Induction Chemotherapy
Vinblastine
Bleomycin
Cell Lineage

Keywords

  • chemotherapy
  • international index
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9720cf73e36e422d93d526fe8edd473a,
title = "Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma - An experience from a Medical Center in Southern Taiwan",
abstract = "A retrospective analysis was performed of 117 non-Hodgkin's lymphoma (NHL) patients (72 male and 45 female, mean age 55 years) treated at NCKUH between July 1988 and December 1993. Of the 115 patients who could be classified by Ann Arbor staging system, 26 patients (22.2{\%}) were in stage 1; 23 (19.7{\%}) in stage 2; 29 (24.8{\%}) in stage 3; and 37 (31.6{\%}) in stage 4. According to the International Working Formulation, three patients (2.6{\%}) were low grade NHL, 90 (76.9{\%}) were intermediate, and 8 (6.8{\%}) were high grade NHL. Histologically, diffuse large cell NHL accounted for 52.1{\%} of cases, followed by 16.2{\%} of cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80{\%}) cases exhibiting B-cell origin, 17 (18{\%}) cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80{\%}) cases exhibiting, B-cell-origin, 17 (18{\%}) cases exhibiting T-cell origin and 2 (2{\%}) cases were of null cell type. All patients underwent two groups of induction chemotherapy, either CHOP (Cyclophosphamide, Epirubicin, Oncovin, and Prednisolone) or 'modified' COPBLAM (Cyclophosphamide, Epirubicin, Oncovin, Vinblastine, Bleomycin, Procarbazine, and Prednisolone). Seventy-two cases treated through COPBLAM and 45 cases treated through CHOP were evaluated. The response rate (RR) to COPBLAM treatment was 72.2{\%} and was 68.9{\%} for the CHOP group (P = 0.51). The 5-year overall survival rate (OAS) was 44.1{\%} for COPBLAM, versus 40{\%} for CHOP (P = 0.15). The disease-free survival (DFS) was 72.6{\%} at 63 months for COPBLAM and 58{\%} at 51 months for CHOP (P = 0.16). Neither B cell nor T-cell lineages of NHL showed any statistical difference in RR (P = 0.53), DFS (P = 0.58) or OAS (P = 0.97) to the different treatments. Using multiple logistic analysis, two independent factors, high LDH and advanced stage, were found to adversely affect the rate of complete remission. The application of the International Prognostic Index to our patients needs modification, which suggests the necessity of more evaluation before it can accurately be applied to all international series of NHL.",
keywords = "chemotherapy, international index, non-Hodgkin's lymphoma",
author = "Hsieh, {C. I.} and Su, {W. C.} and Chien, {C. H.} and Cuo, {Y. L.} and Chen, {T. Y.} and Kao, {R. H.} and Tsao, {C. J.}",
year = "1996",
month = "3",
day = "25",
language = "English",
volume = "12",
pages = "69--82",
journal = "Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences",
issn = "1607-551X",
publisher = "高雄醫學大學",
number = "2",

}

TY - JOUR

T1 - Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma - An experience from a Medical Center in Southern Taiwan

AU - Hsieh, C. I.

AU - Su, W. C.

AU - Chien, C. H.

AU - Cuo, Y. L.

AU - Chen, T. Y.

AU - Kao, R. H.

AU - Tsao, C. J.

PY - 1996/3/25

Y1 - 1996/3/25

N2 - A retrospective analysis was performed of 117 non-Hodgkin's lymphoma (NHL) patients (72 male and 45 female, mean age 55 years) treated at NCKUH between July 1988 and December 1993. Of the 115 patients who could be classified by Ann Arbor staging system, 26 patients (22.2%) were in stage 1; 23 (19.7%) in stage 2; 29 (24.8%) in stage 3; and 37 (31.6%) in stage 4. According to the International Working Formulation, three patients (2.6%) were low grade NHL, 90 (76.9%) were intermediate, and 8 (6.8%) were high grade NHL. Histologically, diffuse large cell NHL accounted for 52.1% of cases, followed by 16.2% of cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting B-cell origin, 17 (18%) cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting, B-cell-origin, 17 (18%) cases exhibiting T-cell origin and 2 (2%) cases were of null cell type. All patients underwent two groups of induction chemotherapy, either CHOP (Cyclophosphamide, Epirubicin, Oncovin, and Prednisolone) or 'modified' COPBLAM (Cyclophosphamide, Epirubicin, Oncovin, Vinblastine, Bleomycin, Procarbazine, and Prednisolone). Seventy-two cases treated through COPBLAM and 45 cases treated through CHOP were evaluated. The response rate (RR) to COPBLAM treatment was 72.2% and was 68.9% for the CHOP group (P = 0.51). The 5-year overall survival rate (OAS) was 44.1% for COPBLAM, versus 40% for CHOP (P = 0.15). The disease-free survival (DFS) was 72.6% at 63 months for COPBLAM and 58% at 51 months for CHOP (P = 0.16). Neither B cell nor T-cell lineages of NHL showed any statistical difference in RR (P = 0.53), DFS (P = 0.58) or OAS (P = 0.97) to the different treatments. Using multiple logistic analysis, two independent factors, high LDH and advanced stage, were found to adversely affect the rate of complete remission. The application of the International Prognostic Index to our patients needs modification, which suggests the necessity of more evaluation before it can accurately be applied to all international series of NHL.

AB - A retrospective analysis was performed of 117 non-Hodgkin's lymphoma (NHL) patients (72 male and 45 female, mean age 55 years) treated at NCKUH between July 1988 and December 1993. Of the 115 patients who could be classified by Ann Arbor staging system, 26 patients (22.2%) were in stage 1; 23 (19.7%) in stage 2; 29 (24.8%) in stage 3; and 37 (31.6%) in stage 4. According to the International Working Formulation, three patients (2.6%) were low grade NHL, 90 (76.9%) were intermediate, and 8 (6.8%) were high grade NHL. Histologically, diffuse large cell NHL accounted for 52.1% of cases, followed by 16.2% of cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting B-cell origin, 17 (18%) cases exhibiting diffuse mixed NHL. Immunophenotype analysis was available in 95 cases, which revealed 76 (80%) cases exhibiting, B-cell-origin, 17 (18%) cases exhibiting T-cell origin and 2 (2%) cases were of null cell type. All patients underwent two groups of induction chemotherapy, either CHOP (Cyclophosphamide, Epirubicin, Oncovin, and Prednisolone) or 'modified' COPBLAM (Cyclophosphamide, Epirubicin, Oncovin, Vinblastine, Bleomycin, Procarbazine, and Prednisolone). Seventy-two cases treated through COPBLAM and 45 cases treated through CHOP were evaluated. The response rate (RR) to COPBLAM treatment was 72.2% and was 68.9% for the CHOP group (P = 0.51). The 5-year overall survival rate (OAS) was 44.1% for COPBLAM, versus 40% for CHOP (P = 0.15). The disease-free survival (DFS) was 72.6% at 63 months for COPBLAM and 58% at 51 months for CHOP (P = 0.16). Neither B cell nor T-cell lineages of NHL showed any statistical difference in RR (P = 0.53), DFS (P = 0.58) or OAS (P = 0.97) to the different treatments. Using multiple logistic analysis, two independent factors, high LDH and advanced stage, were found to adversely affect the rate of complete remission. The application of the International Prognostic Index to our patients needs modification, which suggests the necessity of more evaluation before it can accurately be applied to all international series of NHL.

KW - chemotherapy

KW - international index

KW - non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0029877703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029877703&partnerID=8YFLogxK

M3 - Article

C2 - 8709176

AN - SCOPUS:0029877703

VL - 12

SP - 69

EP - 82

JO - Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences

JF - Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences

SN - 1607-551X

IS - 2

ER -